This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Eli Lilly and Company
Q22022
8/4/2022
Mike Mason
President of Lilly Diabetes
type 2 diabetes. And so that's what we're testing in a study. It's one that we're very excited about. And we've already started to see, you know, weekly injectables being used, you know, earlier than just the injection space as more people understand that, you know, a weekly injection through an oral injector is a good experience. And actually some consumers prefer orals, but some actually consume you know, prefer a weekly injection with an oral injector like Montreal and Trulicity has.
Kevin Hearn
Vice President of Investor Relations
Thanks, Mike. Well, thanks for your question. Next caller, please.
Operator
The next caller is Evan Siegerman with BMO Capital Markets. Please go ahead.
You're reading a preview of the LLY Q2 2022 earnings call.
Free account.
Disclaimer